The frontline treatment strategy for newly diagnosed AML

Tapan Kadia, MD, of The University of Texas MD Anderson Cancer Center, Houston, TX, gives an outline of the current frontline treatment strategy for acute myeloid leukemia (AML), and suggests how it may change in the future. Dr Kadia talks on the importance of characterizing patients based on the presence and absence of mutations in order to determine the most appropriate treatment combinations. For example, patients with FLT3 mutations undergo intensive chemotherapy with cladribine, idarubicin, and AraC (CLIA) followed by a FLT3 inhibitor, whereas those with wildtype FLT3 undergo CLIA regimen with venetoclax. This interview took place during the ninth annual meeting of the Society of Hematologic Oncology (SOHO 2021) congress.